Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer.

被引：0
|
作者：
Udagawa, Shohei [1 ]
Osumi, Hiroki [1 ]
Ooki, Akira [1 ]
Wakatsuki, Takeru [1 ]
Fukuoka, Shota [1 ]
Yoshino, Koichiro [1 ]
Tamba, Mikako [1 ]
Ogura, Mariko [1 ]
Takahari, Daisuke [1 ]
Chin, Keisho [1 ]
Yamaguchi, Kensei [1 ]
Shinozaki, Eiji [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
283-237-255; 261-492-3532-2370-7650-2700; 261-566-148; 261-492-9019; 298-145-222-184-4809-5347; 3282-415; 7; 6; 4; 3; 2; 38092-18849; 38092-22188; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：142 / 142
页数：1
相关论文
共 50 条
  • [41] Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colorectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study
    Prager, G.
    Kisro, J.
    Mueller-Huesmann, H.
    von der Heyde, E.
    Stuebs, P.
    Buerkle, D.
    Schmidt, B.
    Forstbauer, H.
    Hagemeyer, N.
    Reichenbach, F.
    Arnold, D.
    Fritsch, R.
    Gerger, A.
    Hegewisch-Becker, S.
    Vogel, A.
    Wagner, A.
    Winder, T.
    Koeberle, D.
    Stintzing, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S11 - S11
  • [42] Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma
    Chen, Tiffany Y.
    Lorch, Jochen H.
    Wong, Kristine S.
    Barletta, Justine A.
    HISTOPATHOLOGY, 2020, 77 (02) : 314 - 320
  • [43] Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
    Van Cutsem, Eric
    Huijberts, Sanne
    Grothey, Axel
    Yaeger, Rona
    Cuyle, Pieter-Jan
    Elez, Elena
    Fakih, Marwan
    Montagut, Clara
    Peeters, Marc
    Yoshino, Takayuki
    Wasan, Harpreet
    Desai, C. Jayesh
    Ciardiello, Fortunato
    Gollerkeri, Ashwin
    Christy-Bittel, Janna
    Maharry, Kati
    Sandor, Victor
    Schellens, Jan Hm
    Kopetz, Scott
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (17) : 1460 - +
  • [44] Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study
    Kato, T.
    Kotani, D.
    Takashima, A.
    Satoh, T.
    Masuishi, T.
    Komatsu, Y.
    Shiozawa, M.
    Esaki, T.
    Izawa, N.
    Takeuchi, S.
    Bando, H.
    Iwasa, S.
    Hasegawa, H.
    Yamaguchi, T.
    Taniguchi, H.
    Yamada, S.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S21 - S22
  • [45] Clinical outcomes of patients (Pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated with first-line (1L) chemotherapy regimens
    Parikh, A.
    Tabernero, J.
    Vieira, M. C.
    Kponee-Shovein, K.
    Li, B.
    Cheng, M.
    Liu, J.
    Kang, H.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S44 - S45
  • [46] Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
    Tabernero, J.
    Velez, L.
    Trevino, T. L.
    Grothey, A.
    Yaeger, R.
    Van Cutsem, E.
    Wasan, H.
    Desai, J.
    Ciardiello, F.
    Yoshino, T.
    Gollerkeri, A.
    Maharry, K.
    Christy-Bittel, J.
    Kopetz, S.
    ESMO OPEN, 2021, 6 (06)
  • [47] Safety and efficacy of encorafenib, binimetinib, plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer: Results of a prospective study as an expanded access program
    Takashima, Atsuo
    Kotani, Daisuke
    Kato, Takeshi
    Satoh, Taroh
    Masuishi, Toshiki
    Komatsu, Yoshito
    Shiozawa, Manabu
    Esaki, Taito
    Izawa, Naoki
    Takeuchi, Shinji
    Bando, Hideaki
    Iwasa, Satoru
    Hasegawa, Hiroko
    Yamaguchi, Toshifumi
    Taniguchi, Hiroya
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [48] Differential radiographic appearance of BRAF V600E mutant metastatic colorectal cancer (mCRC) in patients matched by primary tumor location.
    Greene, Claire
    Atreya, Chloe Evelyn
    McWhirter, Ryan
    Ikram, Nabia
    Van Loon, Katherine
    Venook, Alan P.
    Yeh, Benjamin M.
    Behr, Spencer
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [49] A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
    Baik, Christina
    Cheng, Michael L.
    Dietrich, Martin
    Gray, Jhanelle E.
    Karim, Nagla A.
    ADVANCES IN THERAPY, 2024, 41 (07) : 2586 - 2605
  • [50] Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study
    Smit, E.
    Ahn, M-J
    Dagogo-Jack, I.
    Felip, E.
    Gelsomino, F.
    Johnson, B.
    Johnson, M.
    Negrao, M. V.
    Offin, M.
    Ramalingam, S.
    Sanborn, R.
    Tsao, A.
    Wilner, K.
    Alcasid, A.
    Usari, T.
    Zhang, X.
    Riely, G.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S77 - S78
12345